Trial Profile
A Phase 1 study of KBP-5209 in patients with advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Mar 2022
Price :
$35
*
At a glance
- Drugs Pirotinib (Primary)
- Indications Breast cancer; Lung cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Sihuan Pharmaceutical Holdings Group
- 17 Feb 2022 Status changed from recruiting to completed.
- 02 Jun 2017 Results (n=23) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 29 Mar 2016 According to a Sihuan Pharmaceutical Holdings media release, enrollment in the first three cohort groups have been completed and the fourth cohort group is in progress.